| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 26.04B | 25.45B | 23.25B | 18.71B | 15.27B | 12.56B |
| Gross Profit | 21.28B | 20.91B | 18.63B | 15.55B | 12.78B | 10.48B |
| EBITDA | 7.09B | 7.08B | 6.72B | 5.24B | 4.25B | -157.00M |
| Net Income | 3.86B | 3.87B | 3.80B | 2.93B | 2.26B | -1.96B |
Balance Sheet | ||||||
| Total Assets | 34.84B | 37.57B | 34.53B | 30.39B | 21.60B | 20.10B |
| Cash, Cash Equivalents and Short-Term Investments | 10.64B | 14.29B | 13.26B | 10.00B | 8.60B | 7.42B |
| Total Debt | 4.08B | 5.20B | 4.52B | 6.59B | 2.90B | 3.68B |
| Total Liabilities | 15.18B | 17.62B | 15.09B | 14.32B | 6.67B | 7.10B |
| Stockholders Equity | 19.69B | 19.98B | 19.45B | 16.07B | 14.93B | 12.99B |
Cash Flow | ||||||
| Free Cash Flow | 4.62B | 7.17B | 5.97B | 4.68B | 2.99B | 1.96B |
| Operating Cash Flow | 4.75B | 7.33B | 6.84B | 5.71B | 3.85B | 2.57B |
| Investing Cash Flow | -2.94B | -2.45B | -961.00M | -4.60B | -1.28B | -1.75B |
| Financing Cash Flow | -5.10B | -3.84B | -2.59B | 267.00M | -1.39B | -29.00M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | ¥40.21B | 22.84 | ― | 0.36% | 18.02% | 46.43% | |
76 Outperform | ¥68.94B | 33.20 | ― | 0.89% | 30.25% | 67.87% | |
73 Outperform | ¥20.84B | 19.40 | ― | 1.22% | 8.09% | 8.53% | |
68 Neutral | ¥52.79B | 12.53 | ― | 1.51% | 10.84% | 5.13% | |
60 Neutral | $48.67B | 4.58 | -11.27% | 4.14% | 2.83% | -41.78% | |
60 Neutral | ¥82.09B | 20.18 | ― | ― | 27.02% | 158.11% |
ZIGExN Co., Ltd. announced the progress of its share repurchase program, initially resolved in May 2025. Despite the authorization to repurchase up to 1.5 million shares, no shares were repurchased in September 2025. Cumulatively, the company has repurchased 883,300 shares for approximately JPY 402 million, indicating a strategic move to manage its capital structure.
The most recent analyst rating on (JP:3679) stock is a Buy with a Yen521.00 price target. To see the full list of analyst forecasts on ZIGExN Co., Ltd. stock, see the JP:3679 Stock Forecast page.
ZIGExN Co., Ltd. has acquired Alpha Staff Co., Ltd., making it a wholly owned subsidiary to enter the growing resort sector and temporary staffing market. This strategic move aims to capitalize on the increasing number of inbound tourists and labor shortages, enhancing profitability and creating synergies between Alpha Staff and ZIGExN’s existing businesses.
The most recent analyst rating on (JP:3679) stock is a Buy with a Yen521.00 price target. To see the full list of analyst forecasts on ZIGExN Co., Ltd. stock, see the JP:3679 Stock Forecast page.
ZIGExN Co., Ltd. reported its consolidated financial results for the first quarter of FY3/2026, showing a revenue increase of 9.5% year-over-year. Despite the revenue growth, the company experienced a slight decline in net income and income before tax compared to the previous year. The financial position remained stable with a slight decrease in total assets and equity. The company maintained its dividend forecast and did not revise its financial forecast for the full fiscal year, indicating confidence in its ongoing operations.
ZIGExN Co., Ltd. announced the progress of its share repurchase program, initially resolved in May 2025. The company repurchased 199,400 common shares for JPY 91,625,500 between July 1 and July 31, 2025, as part of a larger plan to buy back up to 1.5 million shares by March 2026. This move is likely aimed at enhancing shareholder value and optimizing capital structure.
ZIGExN Co., Ltd.’s subsidiary, REJOB Co., Ltd., has acquired AnyCareer Inc., a company specializing in job placement for pharmacists, to enhance its recruitment capabilities in the pharmacy sector. This acquisition aims to leverage AnyCareer’s extensive client base and operational expertise to create synergies with REJOB’s existing services, thereby expanding its market presence and addressing the growing demand for pharmacists amid a labor shortage.